Capivasertib
Truqap (capivasertib) is a small molecule pharmaceutical. Capivasertib was first approved as Truqap on 2023-11-16. The pharmaceutical is active against RAC-beta serine/threonine-protein kinase, RAC-gamma serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Truqap
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Capivasertib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRUQAP | AstraZeneca | N-218197 RX | 2023-11-16 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| truqap | New Drug Application | 2025-11-14 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CAPIVASERTIB, TRUQAP, ASTRAZENECA | |||
| 2028-11-16 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 16 | 6 | — | 2 | 29 |
| Prostatic neoplasms | D011471 | — | C61 | 4 | 4 | 3 | — | — | 10 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | 4 | 1 | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 1 | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 8 | 2 | — | — | — | 9 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 2 | — | — | — | 5 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 3 | 3 | — | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | — | 3 | — | — | — | 3 |
| Adenocarcinoma | D000230 | — | — | — | 3 | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 3 | — | — | — | 3 |
| Uterine cervical neoplasms | D002583 | — | — | 2 | 2 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 2 | — | — | — | 2 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Pharmacological phenomena | D000069437 | — | — | 2 | — | — | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 1 | — | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
| Chondrosarcoma | D002813 | — | — | 1 | — | — | — | — | 1 |
| Acinar cell carcinoma | D018267 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Capivasertib |
| INN | capivasertib |
| Description | Capivasertib is an aminopiperidine that is piperidine substituted by 7H-pyrrolo[2,3-d]pyrimidin-4-yl, amino, and [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]aminocarbonyl groups at positions 1, 4, and 4, respectively. It is a pan-AKT kinase inhibitor used in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations. It has a role as an antineoplastic agent and an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is a pyrrolopyrimidine, an aminopiperidine, a piperidinecarboxamide, a member of monochlorobenzenes, a primary alcohol and a secondary carboxamide. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1143532-39-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2325741 |
| ChEBI ID | — |
| PubChem CID | 25227436 |
| DrugBank | DB12218 |
| UNII ID | WFR23M21IE (ChemIDplus, GSRS) |
Target
Agency Approved
AKT2
AKT2
Organism
Homo sapiens
Gene name
AKT2
Gene synonyms
NCBI Gene ID
Protein name
RAC-beta serine/threonine-protein kinase
Protein synonyms
murine thymoma viral (v-akt) homolog-2, PKB beta, Protein kinase Akt-2, Protein kinase B beta, putative v-akt murine thymoma viral oncoprotein 2, rac protein kinase beta, RAC-PK-beta, v-akt murine thymoma viral oncogene homolog 2
Uniprot ID
Mouse ortholog
Akt2 (11652)
RAC-beta serine/threonine-protein kinase (Q60823)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Truqap – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,589 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,470 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use